MSD
Pembrolizumab/Lenvatinib
Biodrugs/ Drugs
Cancer
Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor
2Phase II in Spain,
1Phase I